Migon

Flunarizine BP

Composition : Migon-S Tablet : Each Film coated tablet contains Flunarizine Smg as Flunarizine
Dihydrochloride BP.
Migon-1 0 Tablet: Each Film Coated tablet contains Flunarizine 1 Omg as Flunarizine Dihydrochloride SP.
Indications: Flunarizine tablets are indicated for the\! treatment of prophylaxis of classic (with aura) or common (without aura) migraine, Symptomatic treatment of vestibular vertigo (due to a diagnosed functional disorder of the vestibular system), Peripheral vascular disease (PVD), Motion sickness, Refractory epilepsy resistant to conventoinal antiepilepitc therapy.
Dosage and administration: Adults and elderly-Migraine prophylaxis: Starting Dose- 10 mg daily (at night) for adult patients aged 18 to 64 years and 5 mg daily (at night) for elderly patients aged 65 years and older. If, during this treatment, depressive, extra pyramidal W other unacceptable adverse experiences occur, administration should be discontinued. If, after 2 months of this initial treatment, no significant improvement is observed, the patient should be considered a non-responder and administration should be discontinued.
Maintenance Treatment: If the patient is responding satisfactorily and a maintenance treatment is needed, the dose should be decreased to 5 days treatment at the same daily dose with two successive medicine free days. Even if the prophylactic maintenance treatment is successful and well tolerated, it should be interrupted after 6 months and it should be re-initiated only if the patient relapses. Vertigo & motion sickness: 10-20 mg daily for adults and 5 mg daily for children (>40 kg. Peripheral Vascular disease: 10 mg twice daily, up to 30 mg per day if required. Epileptic seizure: 15-20 mg daily in adults and 5 to 10 mg daily for children as an add-on therapy. Or, as directed by the registered physician.
Side effects: Most common side effects of this medicine are: Depression, rhinitis, insomnia, somnolence, constipation, fatigue, anxiety, nausea, dry mouth, weight gain etc.
Contraindication: It is contraindicated in patients with known hypersensitivity to Flunarizine.
This medicine is contraindicated for following patients: depressive illness, or with pre-existing symptoms of parkinson's disease or other extra pyramidal disorders."
Use in pregnancy and lactation: Pregnancy: There are no adequate data and well controlled studies in pregnant women. lactation : It is unknown whether flunarizine is excreted in human milk. This tablet should be used during pregnancy only if clearly needed. Caution should be exercised when this tablet is administered to a nursing woman.
Drug interactions: Galactorrhoea has been reported in few women on oral contraceptives within the first two months of Flunarizine treatment. Excessive sedation can occur when alcohol, hypnotics or tranquillisers are taken simultaneously with flunarizine. Chronic admin~tration of flunarizine did not affect the disposition of phenytoin, carbamazepine, valproate or phenobarbital.
Precautions: Flunarizine may give rise to extrapyramidal and depressive symptoms and reveal parkinsonism, especially in elderly patients. therefore, it should be used with caution in such patients. Flunarizine tablets contain lactose monohydrate. Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine. Since sedation or drowsiness occurs in some patients during treatment with Flunarizine, patients should be cautioned against 11 activities which require alertness (e.g. operating machinery or a motor vehicle).
Overdose: Symptoms of over dosage are sedation, agitation and tachycardia. Supportive treatment of acute over dosage consists of charcoal administration.
Storage: Store below 25˚ C in a dry place.
Packing: Migon-S tablet: Each box contains 4x14's tablets in blister pack.
Migon-1 0 Tablet: Each box contains 4x14's tablets in blister pack.